# Sepsis {#sec-sepsis}

A **life-threatening organ dysfunction** due to a **dysregulated** host **response to infection**, where:

:::column-margin
The definition of sepsis has remained necessarily vague, as the clinical diagnosis of sepsis is based on a constellation of non-specific features. Drawing a line which neatly includes the septic and excludes other illnesses is therefore not currently possible.\
\
This is the [Sepsis-3](https://jamanetwork.com/journals/jama/fullarticle/2492881) definition, which moved the definitional goalposts from trying to pin down "sepsis" to trying to identify patients with clinically suspected infection who had a high mortality.
:::

* **Organ dysfunction**\
⩾2 ↑ in SOFA score.
* **Septic shock**\
Sepsis, with:
	* ↓ BP requiring vasopressors
	* Lactate >2mmol/L

:::column-margin
Management of febrile neutropaenia and neutropaenic sepsis is covered under @sec-febrile_neut.
:::

## Epidemiology and Risk Factors

Major global healthcare burden:

* High number of cases
* High mortality\
~30%.

Host response is highly heterogenous, and is affected by:

* Patient factors:
	* Comorbidities
	* Genetics
* Pathogen factors:
	* Pathogen virulence
	* Location of infection

: Immunocompromised Host Infectious Organisms by Immune Deficiency Type

+---------------------------+---------------------------------------+--------------------------+----------------+------------+
| Immune Deficiency         | Causes                                | Bacteria                 | Fungi          | Viruses    |
+===========================+=======================================+==========================+================+============+
| **Neutrophils**           | * Acute leukaemia                     | * Gram-negative bacteria | * Candida      |            |
|                           | * Myelodysplastic                     | * Gram-positive bacteria | * Aspergillus  |            |
|                           |   syndromes                           | * Nocardia               | * Mucor        |            |
|                           | * Chemotherapy-induced                |                          |                |            |
|                           |   neutropenia                         |                          |                |            |
+---------------------------+---------------------------------------+--------------------------+----------------+------------+
| **Monocytes/Macrophages** | * Acute/chronic myeloid leukaemia     | * Pseudomonas aeruginosa | * Histoplasma  | * HSV      |
|                           | * Allogeneic HSCT                     | * Staphylococcus aureus  | * Candida      | * VZV      |
|                           | * Haemophagocytic lymphohistiocytosis | * Salmonella             |                |            |
|                           | * Steroids                            | * Listeria               |                |            |
|                           | * Mycophenolate mofetil               | * Legionella             |                |            |
|                           | * Tacrolimus                          | * Brucella               |                |            |
|                           | * Basiliximab                         | * Mycobacteria           |                |            |
|                           | * Belatacept                          |                          |                |            |
+---------------------------+---------------------------------------+--------------------------+----------------+------------+
| **B lymphocytes**         | * Multiple myeloma                    | * Streptococcus          |                |            |
|                           | * B cell lymphoma                     |   pneumoniae             |                |            |
|                           | * Chronic lymphocytic leukaemia       | * Streptococcus pyogenes |                |            |
|                           | * Allogeneic HSCT                     | * Hemophilus influenzae  |                |            |
|                           | * Splenectomy                         | * Campylobacter          |                |            |
|                           | * Steroids                            | * Salmonella             |                |            |
|                           | * Chemotherapy                        | * Mycoplasma             |                |            |
|                           | * CAR-T cells                         |                          |                |            |
|                           | * Rituximab                           |                          |                |            |
+---------------------------+---------------------------------------+--------------------------+----------------+------------+
| **Humoral**               | * Multiple myeloma                    | * Streptococcus          |                |            |
|                           | * Chronic lymphocytic leukaemia       |   pneumoniae             |                |            |
|                           | * Drug-inducedhypogammaglobulinaemia  | * Streptococcus pyogenes |                |            |
|                           | * SOT                                 | * Hemophilus influenzae  |                |            |
|                           | * Rituximab                           | * Mycoplasma             |                |            |
|                           | * Ibrutinib                           |                          |                |            |
|                           | * Daratumumab                         |                          |                |            |
|                           | * Cyclophosphamide                    |                          |                |            |
+---------------------------+---------------------------------------+--------------------------+----------------+------------+
| **T lymphocytes**         | * HIV                                 | * Mycobacteria           | * Pneumocystis | * HSV      |
|                           | * T-cell leukaemia                    |                          | * Aspergillus  | * CMV      |
|                           | * T-cell lymphoma                     |                          | * Cryptococcus | * EBV      |
|                           | * Hodgkin disease                     |                          | * Toxoplasma   | * JC virus |
|                           | * SOT                                 |                          |                |            |
|                           | * Steroids                            |                          |                |            |
|                           | * Fludarabine                         |                          |                |            |
|                           | * Alemtuzumab                         |                          |                |            |
|                           | * Sirolimus                           |                          |                |            |
|                           | * Tacrolimus                          |                          |                |            |
|                           | * Cyclosporine                        |                          |                |            |
|                           | * Azathioprine                        |                          |                |            |
|                           | * Methotrexate                        |                          |                |            |
|                           | * Daratumumab                         |                          |                |            |
+---------------------------+---------------------------------------+--------------------------+----------------+------------+


## Pathophysiology

Progression from a localised infection to systemic involvement requires:

* Activation of pattern-recognition receptors
	* Toll-like receptors
	* C-type lectin receptors
	* Retinoic acid inducible gene-1-like receptors
* Receptor activation leads to complex, simultaneous alteration of multiple metabolic pathways:
	* Pro-inflammatory
	* Anti-inflammatory\
	Simultaneously with pro-inflammatory processes.
	* Neurohormonal
	* Metabolic change
	* Coagulation activation\
	Tend towards a prothrombotic, antifibrionolytic state which may promote microvascular thrombosis and organ ischaemia.
	* Macrovascular dysfunction
	* Microvascular dysfunction
	* Endothelial dysfunction
		* Glycocalyx disruption resulting in ↑ fluid extravasation


Immune paralysis:

* Survival of the initial septic phase may lead to:
	* A dysfunctional immune system
	* Infections classically associated with immunocompromise


Vasodilation occurs via several mechanisms:

* Acidosis
	* K^+^ efflux leading to membrane hyperpolarisation\
	↓ Ca^2+^ entry into vascular smooth muscle.
	* Catecholamine resistance
* ↑ NO production\
Induced by cytokines and bacterial endotoxin.
* Adrenal suppression
* Endogenous vasopressin suppression


Septic cardiomyopathy:

* ↓ Diastolic function

### Aetiology

Any progression of localised infection may lead to sepsis; the most common in adults include:

* Lung\
~60%.
* Abdominal\
~20%.
* Primary bacteraemia
* Renal or GU

:::column-margin
Lung causes are less common in children, with the difference made up with CNS infections and ↑ primary bacteraemia.
:::

: Source of Infection by Incidence and System

+----------------------+-----------------------+-------------------------------------+----------------------------+
| Organ System         | Common                | Uncommon                            | ICU-Associated             |
+======================+=======================+=====================================+============================+
| **Systemic**         | * Viral               | * Malaria                           |                            |
|                      | * Primary bloodstream | * Tuberculosis                      |                            |
+----------------------+-----------------------+-------------------------------------+----------------------------+
| **Respiratory**      | * Pneumonia           | * Epiglottitis                      | * VAP                      |
|                      | * *Dental*            | * Oropharyngeal abscess             | * HAP                      |
|                      | * *Sinusitis*         | * Pleuritis                         | * Sinusitis                |
|                      | * *Otitis*            |                                     |                            |
|                      | * *Mastoiditis*       |                                     |                            |
+----------------------+-----------------------+-------------------------------------+----------------------------+
| **Cardiovascular**   | * Devices             | * Endocarditis                      | * CLABSI                   |
|                      |     * PPM             |     * Prosthetic valves             |                            |
|                      |                       | * Pericarditis                      |                            |
|                      |                       |                                     |                            |
+----------------------+-----------------------+-------------------------------------+----------------------------+
| **Neurological**     |                       | * Meningitis                        | * EVD-associated           |
|                      |                       | * Encephalitis                      |    * Ventriculitis         |
|                      |                       | * *Discitis*                        |    * Meningitis            |
|                      |                       | * *Epidural abscess*                |                            |
|                      |                       | * *V-P shunt*                       |                            |
+----------------------+-----------------------+-------------------------------------+----------------------------+
| **Genitourinary**    | * UTI                 | * Pyelonephritis                    | * Acalculous cholecystitis |
|                      | * CAUTI               | * Endometritis                      |                            |
|                      | * PID                 | * *Prostatitis*                     |                            |
|                      |                       | * Tampon retention\                 |                            |
|                      |                       | Streptococcal toxic shock.          |                            |
+----------------------+-----------------------+-------------------------------------+----------------------------+
| **Gastrointestinal** | * Cholecystitis       | * Spontaneous bacterial peritonitis | * *C. difficile*           |
|                      | * Cholangitis         | * Polymicrobial peritonitis         |                            |
|                      | * Pancreatitis        | * Infective colitis                 |                            |
|                      | * Diverticulitis      |     * *C. difficile*                |                            |
|                      | * Appendicitis        | * Liver abscess                     |                            |
|                      |                       | * Splenic abscess                   |                            |
+----------------------+-----------------------+-------------------------------------+----------------------------+
| **Integumentary**    | * Cellulitis          | * Septic arthritis                  | * Surgical site infections |
|                      |                       | * Osteomyelitis                     | * Pressure area infections |
|                      |                       | * Prosthetic joints                 |                            |
|                      |                       | * *Psoas abscess*                   |                            |
|                      |                       | * Necrotising fasciitis             |                            |
|                      |                       | * Muscular abscess                  |                            |
+----------------------+-----------------------+-------------------------------------+----------------------------+
| **Notes**:                                                                                                      |
|                                                                                                                 |
| * Classified by relative incidence in each category, rather than overall incidence                              |
| * Sources of potentially *occult* infection are *italicised*                                                    |
+-----------------------------------------------------------------------------------------------------------------+


: Sources of Severe Infection by Type

+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| Source                                  | Gram Positive Cocci                    | Gram Negative Bacilli   | Other                        |
+=========================================+========================================+=========================+==============================+
| **CAP**/**HCAP**                        | * S. pneumoniae                        | * H. influenzae         | * Mycoplasma                 |
|                                         |                                        | * P. aeruginosa         | * L. pneumophila             |
|                                         |                                        | * B. pseudomallei       | * M. pneumoniae              |
|                                         |                                        |                         | * Respiratory Viruses        |
+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| **HAP**/**VAP**                         | * **S. aureus**                        | * **P. aeruginosa**     | * **Aspergillus sp.**        |
|                                         | * **A. baumannii**                     | * **Enterobacterales**  |                              |
+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| **Primary bloodstream**                 | * **Enterococcus spp.**                | * **Candida spp.**      | * **Anaerobes**              |
|                                         |                                        |                         |                              |
+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| **Endocarditis**                        | * S. aureus                            | * HACEK organisms:      |                              |
|                                         | * Streptococcus spp.                   |   * Haemophilus spp.    |                              |
|                                         |                                        |   * Aggregatibacter     |                              |
|                                         |                                        |   * Cardiobacterium     |                              |
|                                         |                                        |   * Eikenella           |                              |
|                                         |                                        |   * Kingella            |                              |
+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| **Meningitis** and                      | * S. pneumoniae                        |                         | * N. meningitidis            |
| **Encephalitis**                        | * S. suis                              |                         | * Listeria                   |
|                                         |                                        |                         | * M. tuberculosis            |
+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| **Healthcare-associated CNS infection** | * **A. baumannii**                     |                         | * **MRSA**                   |
|                                         | * **Coagulase-negative Staphylococci** |                         | * **Staphylococci**          |
+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| **Skin** and **Soft Tissue**            | * Streptococcus A                      | * Enterobacterales      | * Anaerobes                  |
|                                         | * S. aureus                            |                         |                              |
+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| **Intra-abdominal**                     |                                        | * E. coli               | * Anaerobes                  |
|                                         |                                        | * **Enterobacterales**  | * Enteric Viruses            |
|                                         |                                        | * **Enterococcus spp.** | * **Clostridioides**         |
|                                         |                                        | * Shigella              | * **Candida spp.**           |
|                                         |                                        | * Campylobacter         |                              |
|                                         |                                        | * Salmonella            |                              |
+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| **Urinary Tract**                       |                                        | * E. Coli               | * **S. aureus**              |
|                                         |                                        | * **Enterobacterales**  | * **Enterococcus**           |
|                                         |                                        |                         | * **P. aeruginosa**          |
+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| **Surgical Site**                       | * **S. aureus**                        |                         | * According to surgical site |
+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| **Intravascular device**                | * **S. aureus**                        |                         | * **Enterococci**            |
|                                         | * **Candida spp.**                     | * **P. aeruginosa**     |                              |
+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| **Multisystem**                         |                                        | * Leptospira sp.        | * N. meningitidis            |
|                                         |                                        |                         | * M. tuberculosis            |
+-----------------------------------------+----------------------------------------+-------------------------+------------------------------+
| NB: Pathogens in **bold** have increased risk of multi-drug resistance.                                                                   |
+-------------------------------------------------------------------------------------------------------------------------------------------+


## Clinical Features

Heterogenous and non-specific features:

* Tachycardia
* Temperature
	* 35% normothermic
	* 10% hypothermic
	* 55% hyperthermic\
		* Often fluctuant
		* Less likely to be present in the:
			* Elderly
			* Immunosuppressed
			* Malnourished


## Assessment

### History

: Epidemiological Risk Factors

+------------------+---------------------------+------------------------------------+
| Factor           | Details                   | Causative Organisms                |
+==================+===========================+====================================+
| Healthcare       | Recent hospital admission | * Wound infection                  |
|                  |                           | * Hospital-acquired                |
|                  |                           | * MRO                              |
+------------------+---------------------------+------------------------------------+
|                  | Antibiotic                | * MRO                              |
|                  |                           | * Fungal infection                 |
|                  |                           | * Viral infection                  |
|                  |                           | * *C. difficile*                   |
+------------------+---------------------------+------------------------------------+
|                  | Lines and devices         | * Line infection                   |
|                  |                           | * Coagulase-negative staphylococci |
+------------------+---------------------------+------------------------------------+
|                  | Blood Transfusion         | * CMV                              |
|                  |                           | * West Nile virus                  |
|                  |                           | * Parvovirus B19                   |
|                  |                           | * Malaria                          |
|                  |                           | * HTLV                             |
|                  |                           | * Prion disease                    |
+------------------+---------------------------+------------------------------------+
|                  | Leech use                 | * *Aeromonas hydrophlia*           |
+------------------+---------------------------+------------------------------------+
| Travel history   | Tropical                  | * Malaria                          |
|                  |                           | * Dengue                           |
|                  |                           | * Meiliodosis                      |
|                  |                           | * Strongyloidosis                  |
+------------------+---------------------------+------------------------------------+
|                  | LMIC                      | * Tuberculosis                     |
|                  |                           | * Zoonoses                         |
|                  |                           | * Salmonellosis                    |
|                  |                           | * Hepatitis                        |
+------------------+---------------------------+------------------------------------+
|                  | Hospitalised              | * MRO                              |
+------------------+---------------------------+------------------------------------+
| Lifestyle        | Alcohol                   | * Opportunistic                    |
|                  |                           | * Pneumonia                        |
+------------------+---------------------------+------------------------------------+
|                  | IVDU                      | * Primary bacteraemia              |
|                  |                           | * Endocarditis                     |
|                  |                           | * Skin/soft tissue                 |
|                  |                           | * Hepatitis                        |
|                  |                           | * Tetanus                          |
|                  |                           | * Botulism                         |
+------------------+---------------------------+------------------------------------+
| Domestic         | Infectious contact        | * Similar infection                |
+------------------+---------------------------+------------------------------------+
|                  | Spa                       | * Atypical pneumonia               |
|                  |                           |     * *Legionella* spp.            |
|                  |                           |     * *Mycobacterium avium*        |
|                  |                           | * Pseudomonas                      |
|                  |                           | * Fungal                           |
+------------------+---------------------------+------------------------------------+
|                  | Air conditioning          | * Atypical pneumonia               |
|                  |                           | * Pseudomonas                      |
|                  |                           | * Fungus                           |
+------------------+---------------------------+------------------------------------+
|                  | Institutionalised:        | * *Pneumococci*                    |
|                  |                           | * *Meningococci*                   |
|                  | * School                  | * Influenzae                       |
|                  |     * Boarding            | * Tuberculosis                     |
|                  | * Barracks                |                                    |
|                  | * Prison                  |                                    |
|                  | * Nursing home            |                                    |
+------------------+---------------------------+------------------------------------+
| Animals          | Domestic companions:      | * Toxoplasmosis                    |
|                  |                           | * Bartonellosis                    |
|                  | * Cats                    | * *Pasteurella*                    |
|                  | * Dogs                    | * Tularaemia                       |
|                  |                           | * Tuberculosis                     |
|                  |                           | * Capnocytophagus                  |
+------------------+---------------------------+------------------------------------+
|                  | Birds                     | * *Chlamydia*                      |
|                  |                           | * Avian influenzae                 |
|                  |                           | * West Nile virus                  |
|                  |                           | * Toxoplasmosis                    |
|                  |                           | * Salmonellosis                    |
|                  |                           | * *Campylobacter*                  |
+------------------+---------------------------+------------------------------------+
|                  | Rodents                   | * Hantavirus                       |
|                  |                           | * Leptospirosis                    |
|                  |                           | * Listeriosis                      |
|                  |                           | * Rabies                           |
|                  |                           | * Salmonellosis                    |
|                  |                           | * Tularaemia                       |
|                  |                           | * Borreliosis                      |
+------------------+---------------------------+------------------------------------+
|                  | Farm animals:             | * Q-fever                          |
|                  |                           | * Brucellosis                      |
|                  | * Sheep                   | * Chlamydia                        |
|                  | * Cattle                  | * *Mycobacterium bovis*            |
|                  | * Pigs                    | * Toxoplasmosis                    |
|                  | * Goats                   | * E. coli O157:H7                  |
|                  |                           | * Tularaemia                       |
|                  |                           | * Erysipelothrix                   |
|                  |                           | * *Streptococcus suis*             |
+------------------+---------------------------+------------------------------------+
|                  | Horses                    | * Brucellosis                      |
|                  |                           | * Leptospirosis                    |
|                  |                           | * Salmonellosis                    |
|                  |                           | * Anthrax                          |
|                  |                           | * Rabies                           |
+------------------+---------------------------+------------------------------------+
|                  | Ticks                     | * *Rickettsia* spp.                |
|                  |                           | * Borreliosis                      |
+------------------+---------------------------+------------------------------------+
|                  | Bats                      | * Lyssavirus                       |
|                  |                           | * Rabies                           |
|                  |                           | * Salmonellosis                    |
+------------------+---------------------------+------------------------------------+
| Occupational     | Healthcare                | * MRO                              |
|                  |                           | * Exposure-prone procedures        |
|                  |                           |     * HIV                          |
|                  |                           |     * Hepatitis                    |
|                  |                           | * Tuberculosis                     |
+------------------+---------------------------+------------------------------------+
|                  | Soil contact              | * Aeromonas hydrophilia            |
|                  |                           | * Leptospirosis                    |
|                  |                           | * Histoplasmosis                   |
|                  |                           | * Tuberculosis                     |
|                  |                           | * Tetanus                          |
+------------------+---------------------------+------------------------------------+
|                  | Treated water             | * Legionella                       |
|                  |                           | * Pseudomonas                      |
+------------------+---------------------------+------------------------------------+
| Immunocompromise | Vaccination               | * Diptheria                        |
|                  |                           | * Tetanus                          |
|                  |                           | * COVID                            |
|                  |                           | * Influenza                        |
|                  |                           | * *H. influenzae*                  |
|                  |                           | * Pneumococcus                     |
|                  |                           | * *Meningococci*                   |
+------------------+---------------------------+------------------------------------+
|                  | Pregnant                  | * Group B *Streptococci*           |
|                  |                           | * Listeria                         |
+------------------+---------------------------+------------------------------------+
|                  | Splenectomy               | * *Meningococci*                   |
|                  |                           | * Pneumococcus                     |
|                  |                           | * *H. influenzae*                  |
+------------------+---------------------------+------------------------------------+
|                  | Immunosuppressed          | * Opportunistic                    |
|                  |                           | * Fungal                           |
+------------------+---------------------------+------------------------------------+
| Food             | Unpasteurised milk        | * Listeria                         |
|                  |                           | * *E. coli*                        |
|                  |                           | * Brucellosis                      |
|                  |                           | * *Campylobacter*                  |
|                  |                           | * *Mycobacterium bovis*            |
|                  |                           | * Salmonella                       |
|                  |                           | * Shigella                         |
|                  |                           | * *Bacillus cerus*                 |
+------------------+---------------------------+------------------------------------+
|                  | Undercooked meat and eggs | * Salmonella                       |
|                  |                           | * Toxoplasmosis                    |
|                  |                           | * Listeria                         |
+------------------+---------------------------+------------------------------------+
|                  | Shellfish                 | * *Vibrio vulnificus*              |
|                  |                           | * Hepatitis A                      |
+------------------+---------------------------+------------------------------------+


### Exam

### Investigations

**Laboratory**:

* Blood
	* CRP
		* Non-specific marker of inflammation
			* May be more specific for *Strep. pneumoniae* infection\
			This may also better identify patients in whom steroid would be appropriate. 
		* Rises 4-6 hours after onset of infection, doubles ~8 hourly
		* Correlates with severity of infection
			* Rapid ↓ indicates response
	* Procalcitonin
		* Relatively more specific marker of inflammation\
		Elevated in:
			* Bacterial infection\
			Produced in response to bacterial endotoxin.
				* Levels rise in 6-8 hours\
				Prior to cultures flagging positive.
				* Not ↑ in viral or fungal infections
				* Not ↑ in local bacterial infection without a systemic response
			* Burns
			* TLS
			* Major surgery
			* Multi-organ failure
			* ESRD\
			Renally cleared.
		* No better than clinical judgment in discriminating infectious vs. non-infectious causes
		* Expensive, requires serial measurements
	* Blood cultures\
	Prior to antibiotics.
	* Galactomannan
		* Presence suggestive of fungal infection, particularly aspergillosis
		* Risk of false positives from other fungal infections or concomitant β-lactam use
    * (1→3)-β-D-glucan antigen\
    Cell wall component of most fungi. Improves sensitivity and specificity in combination with galactomannan.


## Diagnostic Approach and DDx

Diagnosis of sepsis is difficult.

* Clinical
	* Signs are non-specific
		* Changes with local infection
		* May not be present in:
			* Elderly
			* Immunocompromised
	* Findings may reflect other forms of shock
* Laboratory
	* Markers are non-specific
	* Microbiological samples:
		* Take significant time to process\
		Requires treatment to be initiated in advance of knowing.
		* Must distinguish infection from colonisation\
		Requires clinical interpretation.

:::column-margin
The qSOFA is a quick screening tool to identify patients who should be *considered* for sepsis workup, and requires **⩾2 of**:

* Altered mentation
* RR >22
* SBP <100mmHg
:::

:::column-margin
There is a substantial overlap in features with HLH (see @sec-hlh); consider HLH as a differential diagnosis in septic patients without a source.
:::

## Management {#sec-sepsis_mx}

:::priority
* Early **antibiotics** (**<1 hour**) with **blood cultures** (2-3 sets) **prior**
* Determine haemodynamic goals and target with:
	* **Fluids**
	* **Vasopressors**
:::

**Resuscitation**:\

:::column-margin
Each hour delay in antibiotic administration is associated with a 12% ↓ in survival.
:::

* C
	* **Target MAP** >65mmHg\
	Consider ↑ (e.g. MAP >70mmHg) if renal failure, poorly controlled hypertension.
	* **Fluid resuscitation**\
	10-20mL/kg up to 30mL/kg total.
		* Crystalloid most effective
			* Albumin equivalent outcomes with potentially ↓ total volume delivered, and haemodynamic goals are achieved move quickly
			* Starch harmful
		* Use dynamic measures of fluid responsiveness to assess need for more therapy
			* Passive leg raise
			* Pulse pressure variation
	* **Arterial line**\
	If vasopressors required.
	* **Vasopressors**
		* Noradrenaline 1^st^ line
			* ↑ Preload due to *veno*constriction
			* ↑ SVR due to vasoconstriction
			* Maintain or ↑ CO\
			B~1~ effects ↑ CO, compensating for ↑ in afterload.
		* Consider adrenaline as 2^nd^ line
		* Vasopressin as 3^rd^ line
		* End-of-the line vasopressor options without much supporting evidence include:
			* Methylene blue\
			1mg/kg bolus over ~30 minutes.
			* Hydroxycobalamin\
			5g.
			* Terlipressin
			* Angiotensin II
	* **Assess CO**
		* **Inotropic support** if:
			* Adequately volume resuscitated
			* Evidence of ↓ perfusion:
				* ↑ Lactate
				* ↓ Central capillary refill
				* Echocardiography
			* Pre-existing LV dysfunction
		* VA ECMO\
		Appropriate in selected patients with myocardial dysfunction, acknowledging high mortality of this cohort.


:::column-margin
Early use of noradrenaline is associated with ↓ mortality.
:::

:::column-margin
**Average** total **IV fluid** resuscitation at:

* **6** hours is **~4.2L** ±**1.4L**
* **72** hours is **~6.8L** ±**3L**
:::

**Specific therapy**:

* Pharmacological
	* **Antibiotics**
		* Empirical\
		Tailored to likely sources and resistance patterns.
	* **Corticosteroids**
		* Remain somewhat controversial
		* Appropriate for patients:
			* With another indication for steroids
			* Sepsis with CAP
		* *May* be appropriate in septic patients:
			* Refractory to vasopressors
			* Otherwise high risk
		* Unlikely to change mortality or outcome
		* Will spare vasopressors
		* May ↓ ventilator days and speed shock resolution
	* Toxic Shock cover\
	If treating TSS, or empirical if clinically likely.
		* Clindamycin
		* IVIG
* Procedural
	* Source control
	* Removal of short-term intravascular catheters if catheter-related sepsis is likely\
	This includes arterial catheters. 
* Physical

:::column-margin
My approach is to use corticosteroids in septic patients with:

* CAP
* On previous steroid supplementation
* With noradrenaline ⩾0.15μg/kg/min
:::

**Supportive care**:

* F
	* pH >7.15\
	↑ Cardiac sensitivity to catecholamines.
		* Sodium bicarbonate
		* THAM
	* iCa >1.1mmol/L\
	Very low supporting evidence.
* H
	* Hb >70

**Disposition**:

**Preventative**:


### Marginal and Ineffective Therapies

**Drugs**:

* β-blockade
	* Esmolol probably most well studied
		* Very high control group mortality
		* May reflect reversal of harmful exogenous β-agonists 
* Activated protein C
* Vitamin C
* IVIG\
No proven role outside of TSS.

**Resuscitation targets**:

* CVP targeting
* ScvO~2~ targeting
* PAC targeting\
Use of PAC does not improve and may worsen outcome.


**Blood Purification**:

* High-volume haemofiltration\
CRRT with target dose >35mL/kg/hr.
* Polymyxin B Haemoperfusion\
CRRT with Polymyxin B bound to the filter, which binds bacterial endotoxin.
* High cut-off haemofiltration\
CRRT with larger pores, allowing filtration of middle-molecular weight proteins which include pro- and anti-inflammatory cytokines.


**Other**:

* Hydroxy-ethyl starch resuscitation fluids\
↑ AKI and mortality.


## Anaesthetic Considerations



## Complications

Complications of sepsis include:

* B
	* ARDS
* C
	* Septic cardiomyopathy
* D
	* **Septic encephalopathy**\
	Impaired mental function in the setting of extracranial infection.
		* 10-80% of septic cases
		* ↑ Mortality associated with ↓ GCS
		* Potential contributors include:
			* Bacterial endotoxin
			* Cytokine release
			* Haemodynamic collapse
* F
	* AKI

### Septic AKI

Epidemiology of septic AKI:

* Occurs in 22% of ICU patients with sepsis
* Associated with ↑ in mortality to 38%


Management:

* Preventative\
Most effective method:
	* Low dose vasopressors\
	Achieving a **MAP >80mmHg** may reduce requirement for RRT.
	* Note that excessive **IV fluid is *in*effective**
		* May worsen oedema\
		Aim euvolaemia.
		* Septic AKI is **not a low-flow state**
		* Balanced solutions are beneficial
		* Avoid starch and gelatin colloids
	* Treat the sepsis

## Prognosis

High mortality:

* ICU death 28-40%\
~30% when adjusted for severity.


## Key Studies

**Fluid**:

{{< include /trials/feast.qmd >}}
{{< include /trials/arise.qmd >}}
{{< include /trials/safe.qmd >}}
{{< include /trials/albios.qmd >}}
{{< include /trials/clovers.qmd >}}
{{< include /trials/classic.qmd >}}


**Early Goal Directed Therapy**:

* Early Goal-Directed Therapy is (?was) a protocolised pathway for sepsis management, targeting specific haemodynamic goals in order to maximise DO~2~ and thus restore cellular oxygen balance:
	* CVP 8-12mmHg
	* MAP 65-90mmHg
	* UO >0.5mL/kg/hr
	* ScvO~2~ >70%
	* Haematocrit >30%
* The comfort of this physiological approach did not survive the crucible of real-word RCT evaluation, and EGDT has been subsequently dismissed
* The principles of aggressive, goal-directed (but not CVP and ScvO~2~-directed) therapy live on
{{< include /trials/rivers.qmd >}}
{{< include /trials/arise.qmd >}}
{{< include /trials/process.qmd >}}


**Steroids**:

* The rationale for steroids is that they *may*:
	* C
		* Limit ↓ inotropy due to bacterial endotoxin
		* ↑ Catecholamine function
		* ↓ NO synthetase production
	* I
		* Correct adrenal insufficiency
		* Dampen hyperactive immune response
{{< include /trials/corticus.qmd >}}
{{< include /trials/adrenal.qmd >}}
{{< include /trials/aprocchss.qmd >}}


**Vitamin C**:

* The rationale for Vitamin C is that:
	* Levels are ↓ in the critically ill
	* Oxidative stress is ↑ in the critically ill
	* Vitamin C has antioxidant effects that may alleviate some oxidative stress
{{< include /trials/marik.qmd >}}
{{< include /trials/citris_ali.qmd >}}
{{< include /trials/vitamins.qmd >}}
{{< include /trials/lovit.qmd >}}


**Other**:

{{< include /trials/censer.qmd >}}
{{< include /trials/andromeda_shock.qmd >}}
{{< include /trials/fabled.qmd >}}
{{< include /trials/candisep.qmd >}}
{{< include /trials/triss.qmd >}}
{{< include /trials/morelli.qmd >}}
{{< include /trials/leopards.qmd >}}


---

## References

1. Bellomo R, Kellum JA, Ronco C et al. Acute kidney injury in sepsis. Intensive Care Med. 2017 Jun;43(6):816-828. doi: 10.1007/s00134-017-4755-7. Epub 2017 Mar 31.
1. Bersten, A. D., & Handy, J. M. (2018). Oh’s Intensive Care Manual. Elsevier Gezondheidszorg.
1. [Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension](https://www.nejm.org/doi/full/10.1056/NEJMoa2212663). New England Journal of Medicine. 2023;388(6):499-510.
1. Singer, M., Deutschman, C.S., Seymour, C.W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G.R., Chiche, J.-D., Coopersmith, C.M., Hotchkiss, R.S., Levy, M.M., Marshall, J.C., Martin, G.S., Opal, S.M., Rubenfeld, G.D., van der Poll, T., Vincent, J.-L., Angus, D.C., 2016. [The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)](https://jamanetwork.com/journals/jama/fullarticle/2492881). JAMA 315, 801.
1. Lamontagne F, Masse MH, Menard J, et al. [Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit](https://www.nejm.org/doi/10.1056/NEJMoa2200644). N Engl J Med. 2022;386(25):2387-2398.
1. Bloos F, Held J, Kluge S, et al. [(1→3)-β-d-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial](https://link.springer.com/article/10.1007/s00134-022-06733-x). Intensive Care Med. 2022;48(7):865-875. doi:10.1007/s00134-022-06733-x
1. Meyhoff TS, Hjortrup PB, Wetterslev J, et al. [Restriction of Intravenous Fluid in ICU Patients with Septic Shock. New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2202707). 2022;386(26):2459-2470.
1. O’Grady NP, Barie PS, Bartlett JG, et al. [Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America](https://journals.lww.com/ccmjournal/Fulltext/2008/04000/Guidelines_for_evaluation_of_new_fever_in.40.aspx). Critical Care Medicine. 2008;36(4):1330.
1. Morelli A, Ertmer C, Westphal M, et al. [Effect of Heart Rate Control With Esmolol on Hemodynamic and Clinical Outcomes in Patients With Septic Shock: A Randomized Clinical Trial](https://jamanetwork.com/journals/jama/fullarticle/1752246). JAMA. 2013;310(16):1683-1691. doi:10.1001/jama.2013.278477
1. Cheng MP, Stenstrom R, Paquette K, et al. [Blood Culture Results Before and After Antimicrobial Administration in Patients With Severe Manifestations of Sepsis](https://www.acpjournals.org/doi/10.7326/M19-1696). Ann Intern Med. 2019;171(8):547-554. doi:10.7326/M19-1696
1. Fujii T, Luethi N, Young PJ, et al. [Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial](https://jamanetwork.com/journals/jama/fullarticle/2759414). JAMA. 2020;323(5):423. doi:10.1001/jama.2019.22176
1. Fowler AA III, Truwit JD, Hite RD, et al. [Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial](https://jamanetwork.com/journals/jama/article-abstract/2752063). JAMA. 2019;322(13):1261-1270. doi:10.1001/jama.2019.11825
1. Hernández G, Ospina-Tascón GA, Damiani LP, et al. [Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial](https://jamanetwork.com/journals/jama/article-abstract/2724361). JAMA. 2019;321(7):654-664. doi:10.1001/jama.2019.0071
1. Annane D, Renault A, Brun-Buisson C, et al. [Hydrocortisone plus Fludrocortisone for Adults with Septic Shock](http://www.nejm.org/doi/full/10.1056/NEJMoa1705716). New England Journal of Medicine. 2018;378(9):809-818. doi:10.1056/NEJMoa1705716
1. Venkatesh B, Finfer S, Cohen J, et al. [Adjunctive Glucocorticoid Therapy in Patients with Septic Shock](http://www.nejm.org/doi/full/10.1056/NEJMoa1705835). New England Journal of Medicine. 2018;378(9):797-808. doi:10.1056/NEJMoa1705835
1. Sprung CL, Annane D, Keh D, et al. [Hydrocortisone Therapy for Patients with Septic Shock](http://www.nejm.org/doi/pdf/10.1056/NEJMoa071366). N Engl J Med. 2008;358(2):111-124. doi:10.1056/NEJMoa071366
1. Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. [Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study](https://journal.chestnet.org/article/S0012-3692(16)62564-3/fulltext). CHEST. 2017;151(6):1229-1238. doi:10.1016/j.chest.2016.11.036
1. Maitland K, Kiguli S, Opoka RO, et al. [Mortality after Fluid Bolus in African Children with Severe Infection](http://www.nejm.org/doi/full/10.1056/NEJMoa1101549). New England Journal of Medicine. 2011;364(26):2483-2495. doi:10.1056/NEJMoa1101549
1. [Goal-Directed Resuscitation for Patients with Early Septic Shock](http://www.nejm.org/doi/full/10.1056/NEJMoa1404380). New England Journal of Medicine. 2014;371(16):1496-1506. doi:10.1056/NEJMoa1404380
1. Dünser MW, Dankl D, Petros S, Mer M. Clinical Examination Skills in the Adult Critically Ill Patient. Springer International Publishing; 2018.
1. Timsit JF, Ling L, De Montmollin E, Bracht H, Conway-Morris A, De Bus L, et al. [Antibiotic therapy for severe bacterial infections](https://link.springer.com/10.1007/s00134-025-08063-0). Intensive Care Med [Internet]. 2025 Sept 1.

